Ustekinumab as Induction and Maintenance Therapy for Ulcerative ColitisBruce E. Sands, Colleen Marano, William J. Sandborn et al.|New England Journal of Medicine|2019Cited by 1.2k
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's DiseaseOmoniyi J. Adedokun, William J. Sandborn, Zhenhua Xu et al.|Gastroenterology|2018Cited by 253
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn’s DiseasePaul Rutgeerts, William J. Sandborn, Christopher Gasink et al.|Gastroenterology|2018Cited by 181
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 StudyBruce E. Sands, William J. Sandborn, Brian G. Feagan et al.|Journal of Crohn s and Colitis|2018Cited by 115
Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative ColitisOmoniyi J. Adedokun, William J. Sandborn, Hongyan Zhang et al.|Clinical Gastroenterology and Hepatology|2019Cited by 107